6 unknown. 6 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Unknown 6 |
| Phase 2 | 5 | Unknown 5 |
Follow Covid 19: new trials by email Literature Review of Covid 19 trials Research Report on Covid 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients Normoxic Allogenic UCMSC, Normal saline solution - Covid 19 | Phase 2 / Phase 3 | Unknown | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | 42 | 2021-01-17 | 2021-11-24 |
| Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients Hydroxychloroquine - COVID 19 | Phase 2 / Phase 3 | Unknown | Hamad Medical Corporation | 500 | 2020-08-31 | 2020-08-11 |
| Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients Acacia Senegal, Pectin - COVID 19 | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 110 | 2020-06-01 | 2020-05-12 |
| BromhexIne And Spironolactone For CoronŠ°VirUs Infection Requiring HospiTalization Bromhexine and Spironolactone, Base therapy - COVID 19 | Phase 3 | Unknown | Lomonosov Moscow State University Medical Research and Educational Center | 80 | 2020-05-16 | 2020-06-09 |
| Oral 25-hydroxyvitamin D3 and COVID-19 Oral 25-Hydroxyvitamin D3 - COVID 19 | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 1500 | 2020-04-14 | 2020-06-12 |
| The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients Hydroxychloroquine, Remdesivir, (Standard of Care) SoC - SARS-CoV Infection, COVID 19 | Phase 2 / Phase 3 | Unknown | Oslo University Hospital | 700 | 2020-03-28 | 2020-04-14 |
COVID-19 (6) · Cytokine Release Syndrome (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Coronaviridae Infections (6) · Coronavirus Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Virus Diseases (5) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Shock (1)
Hydroxychloroquine (2) · Bromhexine (1) · Calcifediol (1) · Gum Arabic (1) · Pectins (1) · Saline Solution (1) · Spironolactone (1) · Standard of Care (1) · remdesivir (1)
Al-Neelain University (1) · Hamad Medical Corporation (1) · Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia (1) · Lomonosov Moscow State University Medical Research and Educational Center (1) · Oslo University Hospital (1) · Tehran University of Medical Sciences (1)
Indonesia (1) · Iran (1) · Norway (1) · Russia (1) · Sudan (1)
Ahmad Faried, Prof. MD (1) · Andreas Barratt-Due, MD, PhD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Arash Shirvani, MD, PhD (1) · Arief Nurudin, MD PhD (1) · Inge Christoffer Olsen, PhD (1) · Katerina Nezvalova-Henriksen, Pharm D, PhD (1) · Michael F Holick, PhD,MD (1) · Moawia M Mukhtar, PhD (1) · Mohamadali Sahraian, MD (1) · Mustafa KM Nimeiri, MD (1) · Nasser Al Ansari, FRCPath (1) · Paul Aukrust, MD, Professor (1) · Samekto Wibowo, Prof. MD (1)
PMID 29859173, PMID 32085846, PMID 32214286, PMID 32265310, PMID 32281062, PMID 32756149, PMID 32891160, PMID 33757717, PMID 34251903, PMID 34350582, PMID 35876699, PMID 36695483, PMID 39533001